Mara Ten Kate

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6362945/publications.pdf

Version: 2024-02-01

		361296	395590
78	1,281	20	33
papers	citations	h-index	g-index

84	84	84	2136
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Atrophy subtypes in prodromal Alzheimerâ€™s disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	3.7	102
2	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
3	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70
4	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	3.0	64
5	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	3.0	62
6	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	1.5	60
7	Early- and Late-Onset Depression in Late Life: A Prospective Study on Clinical and Structural Brain Characteristics and Response to Electroconvulsive Therapy. American Journal of Geriatric Psychiatry, 2017, 25, 178-189.	0.6	59
8	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. Neurobiology of Aging, 2018, 61, 75-81.	1.5	52
9	Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging, 2016, 37, 154-160.	1.5	51
10	The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research and Therapy, 2018, 10, 75.	3.0	48
11	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ¹⁸F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. Journal of Nuclear Medicine, 2019, 60, 541-547.	2.8	47
12	Secondary prevention of Alzheimerâ€™s dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	3.0	46
13	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
14	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiology of Aging, 2018, 61, 198-206.	1.5	44
15	Impact of APOE-É›4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging, 2016, 38, 14-20.	1.5	37
16	Retinal layer thickness in preclinical Alzheimer's disease. Acta Ophthalmologica, 2019, 97, 798-804.	0.6	36
17	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67.	1.7	29
18	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 73.	3.0	25

#	Article	IF	Citations
19	Retinal thickness as a potential biomarker in patients with amyloidâ€proven earlyâ€and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 463-471.	1.2	25
20	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. Journal of Psychiatric Research, 2018, 104, 183-191.	1.5	21
21	White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiology of Aging, 2018, 66, 40-48.	1.5	20
22	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Annals of Neurology, 2021, 89, 987-1000.	2.8	20
23	Genome-Wide Association Study of Alzheimerâ€™s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimerâ€™s Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	1.7	20
24	Functional brain network centrality is related to APOE genotype in cognitively normal elderly. Brain and Behavior, 2018, 8, e01080.	1.0	18
25	White matter microstructure disruption in early stage amyloid pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12124.	1.2	16
26	Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. , 2018, 59, 5025.		15
27	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiology of Aging, 2019, 77, 58-65.	1.5	14
28	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 1499-1511.	2.4	14
29	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications, 2021, 3, fcab201.	1.5	14
30	Longitudinal retinal layer changes in preclinical Alzheimerâ€™s disease. Acta Ophthalmologica, 2021, 99, 538-544.	0.6	13
31	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimerâ€™s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
32	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
33	Are Apathy and Depressive Symptoms Related to Vascular White Matter Hyperintensities in Severe Late Life Depression?. Journal of Geriatric Psychiatry and Neurology, 2021, 34, 21-28.	1.2	12
34	Amyloidâ€Î², cortical thickness, and subsequent cognitive decline in cognitively normal oldestâ€old. Annals of Clinical and Translational Neurology, 2021, 8, 348-358.	1.7	9
35	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimerâ€™s disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	4.1	9
36	Regional associations of white matter hyperintensities and early cortical amyloid pathology. Brain Communications, 2022, 4, .	1.5	9

#	Article	IF	Citations
37	Ocular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study. BMC Geriatrics, 2020, 20, 155.	1.1	8
38	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60â€“102 Years. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1609-1617.	1.7	7
39	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
40	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	1.4	7
41	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
42	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.4	1
43	Dataâ€assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. Alzheimer's and Dementia, 2020, 16, e043593.	0.4	1
44	IC-P-108: Impact of ApoE-Æ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P73-P73.		0
45	O2-09-01: Impact of ApoE-É›4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P194-P194.		0
46	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, P9-P10.		0
47	P2-167: Roadmap to the Biomarker-Based Diagnosis of Alzheimer's Disease. , 2016, 12, P679-P680.		0
48	O3â€08â€01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. Alzheimer's and Dementia, 2016, 12, P303.	0.4	0
49	ICâ€Pâ€002: : Roadmap to The Biomarkerâ€Based Diagnosis of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P13.	0.4	0
50	ICâ€Pâ€017: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P23.	0.4	0
51	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P7-P8.		0
52	P1â€284: Grey Matter Connectivity is Associated With Clinical Progression in Nonâ€Demented, Amyloid Positive Patients. Alzheimer's and Dementia, 2016, 12, P528.	0.4	0
53	P2-237: Concordance of [18F] Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P714-P715.		0
54	ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.4	0

#	Article	IF	Citations
55	P3â€269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P935.	0.4	0
56	P4â€146: Largeâ€Vessel Disease and [18F]Flutemetamolâ€Amyloid Deposition in Cognitively Healthy Elderly Twins. Alzheimer's and Dementia, 2016, 12, P1069.	0.4	0
57	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.4	0
58	[P2â€“399]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P783.	0.4	0
59	[P4â€“226]: BEST COMBINATORIAL LOWâ€COST MARKERS TO PREDICT MCI CONVERSION: AN EMIFâ€AD FEDERATION STUDY. Alzheimer's and Dementia, 2017, 13, P1356.	0.4	0
60	[ICâ€Pâ€036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.	0.4	0
61	[ICâ€Pâ€053]: EARLY ALTERATIONS IN RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P43.	0.4	0
62	[ICâ€Pâ€058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
63	[ICâ€Pâ€065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P53.	0.4	0
64	[P1â€“404]: EARLY ALTERATIONS IN RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P429.	0.4	0
65	[P1â€“411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P433.	0.4	0
66	[O2â€“05â€“01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.	0.4	0
67	ICâ€Pâ€066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P59.	0.4	0
68	P1â€418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P465.	0.4	0
69	P1â€525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2018, 14, P533.	0.4	0
70	P3â€445: FACTORS PREDICTING MORTALITY AT THE MEMORY CLINIC AT SIRIRAJ HOSPITAL: 815 THAI COHORT. Alzheimer's and Dementia, 2018, 14, P1286.	0.4	0
71	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.4	0
72	ICâ€Pâ€005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P16.	0.4	0

#	Article	IF	Citations
73	P3â€355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P1221.	0.4	0
74	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.4	0
75	F1â€02â€03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P202.	0.4	0
76	Amyloidâ€Î² deposition in cognitively normal oldestâ€old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e040991.	0.4	0
77	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e042739.	0.4	0
78	Amyloidâ€Î² deposition in cognitively normal oldestâ€old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e042768.	0.4	0